FDA issues draft guidance overhauling pharma container closure requirements

The US FDA issued a draft guidance in August 2026 that would replace its May 1999 guidance on container closure systems for human drugs and biologics, together with the associated May 2002 questions-and-answers document. The draft moves from a dosage-form risk matrix to a product-specific, risk-based and life cycle framework, with extractables and leachables assessment extended to nominally low-risk oral and topical products. It is open for public comment.

Why this mattersPharma packaging suppliers face heavier extractables, leachables and integrity-testing obligations across the product life cycle once the guidance is finalised.

• The FDA issued the draft guidance on container closure systems for human drugs and biological products in August 2026
• It is intended to supersede the May 1999 container closure guidance and the associated May 2002 questions-and-answers guidance
• The draft is currently open for public comment
• Assessment becomes product-specific, covering formulation, route of administration, system design, manufacturing process and clinical use, rather than resting on dosage-form category
• Even nominally low-risk oral and topical products require an adequate evaluation of possible leachables
• Packaging that prepares, delivers or measures a dose, including device constituent parts of combination products, is brought within scope

Relevant to you? Yes No